Literature DB >> 11408247

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

J Gerber1, A Smirnov, A Wellmer, J Ragheb, J Prange, E Schütz, K Wettich, S Kalich, R Nau.   

Abstract

In a rabbit model of Streptococcus pneumoniae meningitis single doses of 10 and 2.5 mg of the glycopeptide LY333328 per kg of body weight reduced bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as ceftriaxone at 10 mg/kg/h (changes in log CFU, -0.29 +/- 0.21 and -0.26 +/- 0.22 versus -0.34 +/- 0.15/ml/h). A dose of 1 mg/kg was bacteriostatic (change in log CFU, 0.01 +/- 0.11/ml/h). In two animals receiving LY333328 at a dose of 40 mg/kg the bacterial titers were reduced by 0.54 and 0.51 log CFU/ml/h. The penetration of CSF by LY333328 was 1 to 5%. The concentrations of lipoteichoic and teichoic acids in CSF and neuronal damage were similar in ceftriaxone- and LY333328-treated animals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408247      PMCID: PMC90624          DOI: 10.1128/AAC.45.7.2169-2172.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis.

Authors:  R Nau; A Wellmer; A Soto; K Koch; O Schneider; H Schmidt; J Gerber; U Michel; W Brück
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.

Authors:  A M Figueiredo; J D Connor; A Severin; M V Vaz Pato; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

3.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.

Authors:  J S Bradley; J D Connor
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129

4.  Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics.

Authors:  L P Jetté; F Lamothe
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

Review 5.  World-wide development of antibiotic resistance in pneumococci.

Authors:  P C Appelbaum
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

6.  Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae.

Authors:  M G Täuber; C A Doroshow; C J Hackbarth; M G Rusnak; T A Drake; M A Sande
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

7.  Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis.

Authors:  F Trostdorf; R R Reinert; H Schmidt; T Nichterlein; K Stuertz; M Schmitz-Salue; I Sadowski; W Brück; R Nau
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

8.  Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.

Authors:  K Stuertz; H Schmidt; F Trostdorf; H Eiffert; M Mäder; R Nau
Journal:  Scand J Infect Dis       Date:  1999

9.  Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.

Authors:  R Nau; T Schmidt; K Kaye; J L Froula; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

Authors:  P F Viladrich; F Gudiol; J Liñares; R Pallarés; I Sabaté; G Rufí; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more
  11 in total

Review 1.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 2.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Authors:  Carole J Boylan; Kristina Campanale; Philip W Iversen; Diane L Phillips; Michael L Zeckel; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Treatment of Drug-resistant Pneumococcal Meningitis.

Authors:  Nida Hameed; Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

Review 5.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

7.  Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.

Authors:  Carmen Cabellos; Antonio Fernàndez; Jose M Maiques; Fe Tubau; Carmen Ardanuy; Pedro F Viladrich; Josefina Liñares; Francesc Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Authors:  Dario Lehoux; Valerie Ostiguy; Cordelia Cadieux; Mireille Malouin; Odette Belanger; Adel Rafai Far; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 9.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 10.  Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.

Authors:  Subhashis Mitra; Usman Saeed; Daniel H Havlichek; Gary E Stein
Journal:  Infect Drug Resist       Date:  2015-07-06       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.